Cytotoxic CD4+ T Cells in Bladder Cancer-A New License to Kill

Adrian G Sacher; Michael St Paul; Christopher J Paige; Pamela S Ohashi

doi:10.1016/j.ccell.2020.06.013

Cytotoxic CD4⁺ T Cells in Bladder Cancer-A New License to Kill

Cancer Cell. 2020 Jul 13;38(1):28-30. doi: 10.1016/j.ccell.2020.06.013.

Authors

Adrian G Sacher¹, Michael St Paul¹, Christopher J Paige¹, Pamela S Ohashi²

Affiliations

¹ Princess Margaret Cancer Centre, University Health Network, 610 University Ave., Toronto, ON M5G 2M9, Canada; Department of Immunology, Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
² Princess Margaret Cancer Centre, University Health Network, 610 University Ave., Toronto, ON M5G 2M9, Canada; Department of Immunology, Faculty of Medicine, University of Toronto, Toronto, ON, Canada. Electronic address: [email protected].

PMID: 32663467
DOI: 10.1016/j.ccell.2020.06.013

Abstract

CD4⁺ T cells with cytotoxic capability are increasingly recognized as potentially key actors in anti-tumor immunity. A new report in Cell elucidates the presence and potential role of a population of cytotoxic CD4⁺ T cells in bladder cancer using single cell sequencing technology.

Publication types

Comment

MeSH terms

CD4-Positive T-Lymphocytes*
Humans
Urinary Bladder Neoplasms*